The growing prevalence of uterine fibroids, especially among women of reproductive age, is fueling the demand for treatment devices. This surge is fu ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

The Veeva Commercial Summit 2025 highlighted the latest innovations connecting sales, marketing and medical — including Veeva AI.

Starting fecal immunochemical testing (FIT) at ages 40 to 49 was associated with reduced colorectal cancer (CRC) incidence ...

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.

The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women receiving endocrine ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and antibodies.

During today's session, GlaxoSmithKline Pharmaceuticals saw its shares climb by 2.21%, with the price reaching Rs 3187.00. This increase marks a notable movement for the stock, which is part of ...

GlaxoSmithKline Pharmaceuticals shares reached an all-time high during today's session, hitting Rs 3,176.60 on the NSE. The stock is currently trading at Rs 3,163.50, marking a 1.45% increase.